Search

Author/Creator Ray, Paul S.

1. Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). (January 2021)

Authors:
Bennett, Charles L.; Hoque, Shamia; Olivieri, Nancy; Taylor, Matthew A.; Aboulafia, David; Lubaczewski, Courtney; Bennett, Andrew C.; Vemula, Jay; Schooley, Benjamin; Witherspoon, Bartlett J.; Godwin, Ashley C; Ray, Paul S.; Yarnold, Paul R.; Ausdenmoore, Henry C.; Fishman, Marc; Herring, Georgne...
Journal:
EClinicalMedicine
Issue:
Volume 31(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. (6th March 2019)

Authors:
Chen, Brian; Nagai, Sumimasa; Armitage, James O.; Witherspoon, Bartlett; Nabhan, Chadi; Godwin, Ashley C.; Yang, Y. Tony; Kommalapati, Anuhya; Tella, Sri Harsha; DeAngelis, Carlo; Raisch, Dennis W.; Sartor, Oliver; Hrushesky, William J.; Ray, Paul S.; Yarnold, Paul R.; Love, Bryan L.; Norris, LeA...
Journal:
Oncologist
Issue:
Volume 24:Number 4(2019)
Page Start:
537
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗